

# InSightec Ltd.

**InSightec Ltd. developed ExAblate® 2000** – a product that integrates Magnetic Resonance Imaging (MRI) with focused ultrasound energy – as a new treatment modality that can replace invasive procedures and provide therapeutic alternatives to millions of patients with serious diseases around the globe. Currently U.S. Food and Drug Administration (FDA) approved to treat uterine fibroids, the company has launched an extensive research program to conduct clinical trials using the technology in other indications including breast, bone, liver, and brain tumors, while continuing clinical trials in uterine fibroids.

## **Brief History**

InSightec was founded in 1999 when GE Healthcare (then GE Medical Systems) and Elbit Imaging transferred their proprietary technology to the company to enable it to concentrate on developing the promising Magnetic Resonance guided Focused Ultrasound Surgery both companies had investigated. Headquartered near Haifa, Israel, the company has over 150 employees, holds over 30 patents with additional intellectual property pending, and has invested more than \$150 million in research, development, and clinical investigations. Its U.S. headquarters are located in Dallas, Texas.

## **ExAblate® 2000**

ExAblate integrates focused ultrasound thermal ablation with GE's MR imaging capabilities to provide a noninvasive surgery for ablating (destroying) targeted tissue. During this outpatient procedure, the patient lies inside the MRI scanner, which provides three-dimensional images of the target and surrounding tissue, enabling precise guidance of the ultrasound waves. High-intensity focused ultrasound waves are directed into the body toward specific tissue and, at the focal point, raise the temperature of the targeted tissue above 60° Celsius, destroying it. The thermal imaging capabilities of the MRI scanner provide real-time feedback on all aspects of the procedure, which gives the physician a high degree of control over its therapeutic outcome.

ExAblate offered women sustained relief from uterine fibroid symptoms for up to two years, with a low incidence of side effects, according to a study published in the August 2007 issue of *Obstetrics and Gynecology*. The 359-patient Mayo Clinic-led collaborative study also showed that destroying as much of the fibroid as possible leads to the most durable symptom relief with 85% of the participants experiencing symptom improvement after one year.

ExAblate is the first FDA-approved focused ultrasound thermal ablation system. The device received the European CE mark and ISO 9001 and is commercially available in the U.S., Israel, Europe and Asia. ExAblate has also received the European CE Mark for pain palliation caused by bone metastases, which represents the potential for expanding this noninvasive technology for oncology applications.

ExAblate has been recognized for its innovation and potential to serve mankind and has been awarded the 2004 European Union Information Society Technologies grand prize, *The Wall Street Journal's* 2004 Technology Innovation Award, and recognition as one of *Advanced Imaging's* 2005 Solutions of the Year. Red Herring 100 Europe 2007 list of the top privately-held technology companies in Europe, the Middle East and Africa (EMEA) and recently was selected as one of the World Economic Forum Technology Pioneer 2008.

## **Team**

The over 150-person InSightec staff includes world-class scientists and engineers with extensive experience in the wide variety of disciplines involved with this enhanced technology and teamed with leading application specialists, manufacturing, service and other personnel. The company is headquartered in Tirat Carmel, Israel, near the port city of Haifa. Its U.S. offices are in Dallas, Texas. It also has offices in Beijing, China, and Tokyo, Japan.

### **Clinical Partners**

InSightec has established clinical collaborations with leading hospitals and medical research institutions around the world. Sites span the United States, Europe, Japan and Israel and include such institutions as:

- Brigham and Women's Hospital of Harvard University, Boston, MA, USA
- The Mayo Clinic, Rochester, MN, USA
- Weill Medical College, Cornell University, New York, N.Y., USA
- University of California, San Diego, California, USA
- Stanford University School of Medicine, Stanford, CA
- Fox Chase Cancer Center, PA, USA
- Focused Ultrasound Foundation, VA, USA
- Toronto General Hospital, Toronto, Canada
- St. Mary's NHS Trust, London, England
- Itabashi Chuo Hospital, Japan
- Breastopia Namba Hospital, Miyazaki, Japan
- Bundang Cha Hospital, S. Korea
- Sheba Medical Center, Tel Aviv, Israel

For more treatment locations, visit our web site [www.insightec.com](http://www.insightec.com)

### **Shareholders**

InSightec is a privately-held company. Its shareholders are Elbit Imaging Ltd., MediTech Advisors LP and General Electric Capital Equity Holdings, Inc., a unit of General Electric Company, together with InSightec management, employees and directors. InSightec also has a worldwide sales and marketing agreement with GE Healthcare, a unit of General Electric Company for the sales and marketing of its ExAblate®2000.

For more information, contact:

InSightec Ltd.  
P.O. Box 2059  
Tirat Carmel 39120, Israel  
Tel: +972-4-813-1313  
Fax: +972-4-813-1322  
[Email: info@insightec.com](mailto:info@insightec.com)

For media inquiries, contact:

Fern Lazar  
Lazar Partners, Ltd.  
Tel: (212) 867-1762  
Email: [flazar@lazarpartners.com](mailto:flazar@lazarpartners.com)

